To further asses the performance of PAC in samples with heterogeneous (wild-type and mutant) transcript expression, we performed PAC on 14 clinical glioblastoma specimens (selected to contain >70% tumor nuclei) that had genomic amplifications of the EGFR oncogene. Here, EGFR is linked to glioblastoma.